# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001144204-15-057696
Filing Date
2015-10-01
Accepted
2015-10-01 16:30:50
Documents
7
Period of Report
2015-11-08
Effectiveness Date
2015-10-01

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | v420890_def14a.htm | DEF 14A | 517079
2 | GRAPHIC | line.gif | GRAPHIC | 43
3 | GRAPHIC | logo_protalix.jpg | GRAPHIC | 25457
4 | GRAPHIC | sig_yossi-maimon.jpg | GRAPHIC | 9221
5 | GRAPHIC | spacer.gif | GRAPHIC | 43
6 | GRAPHIC | v420890_pc1.jpg | GRAPHIC | 1018732
7 | GRAPHIC | v420890_pc2.jpg | GRAPHIC | 318606
| Complete submission text file | 0001144204-15-057696.txt |  | 2408274

Mailing Address 2 SNUNIT ST SCIENCE PARK, POB 455 CARMIEL L3 20100
Business Address 2 SNUNIT ST SCIENCE PARK, POB 455 CARMIEL L3 20100 972-4-988-9488
Protalix BioTherapeutics, Inc. (Filer) CIK: 0001006281 (see all company filings)

EIN.: 650643773 | State of Incorp.: FL | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-33357 | Film No.: 151137359
SIC: 2836 Biological Products, (No Diagnostic Substances)